My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Novo Nordisk A/S Common Stock (NY:NVO)

39.67 -7.75 (-16.34%)

Streaming Delayed Price Updated: 2:58 PM EST, Feb 23, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Novo Nordisk A/S Common Stock

< Previous 1 2

...

13 14 15 16 17 18 19 20 21

...

99 100 Next >

3 Magnificent Stocks Under $100 to Buy Right Now ↗

September 27, 2025

You won't need a huge amount of cash to invest in these great pharma stocks.

Via The Motley Fool

Global Markets Brace for Impact as New U.S. Tariffs Escalate Trade Tensions Amidst Geopolitical Volatility

September 26, 2025

September 26, 2025 – Global financial markets are once again in the throes of uncertainty as the United States unveils a fresh wave of substantial trade tariffs, set to take effect on October 1, 2025....

Via MarketMinute

Consumers Splurge, Intel, GlobalFoundries, Lilly, Paccar, American Woodmark Benefit From New Tariffs ↗

September 26, 2025

To gain an edge, this is what you need to know today.

Via Benzinga

Chinese Biotech Takes Aim At Eli Lilly, Novo Nordisk With New GLP-1 Weight-Loss Drugs As Patent Clocks Tick ↗

September 22, 2025

Via Stocktwits

Topics Intellectual Property

Trump's 100% Pharmaceutical Tariff: The $270 Billion Manufacturing War That Could Reshape Your Medicine Cabinet ↗

September 26, 2025

Trump’s sweeping 100% pharmaceutical tariff starting October 1 triggers massive $270 billion industry investment surge, creating clear stock market winners like Eli Lilly while foreign-de

Via Benzinga

Topics Government World Trade

Eli Lilly's GLP-1 Pill Just Beat Out Novo Nordisk's in a Test. Here's 1 Thing Investors Need to Know. ↗

September 26, 2025

Recent data from a head-to-head trial was positive for Eli Lilly, but it's not the whole story.

Via The Motley Fool

3 Absurdly Cheap Stocks You Can Buy for Less than $100 Right Now ↗

September 26, 2025

These stocks come with some uncertainty, but they have strong fundamentals and trade at low earnings multiples.

Via The Motley Fool

Topics World Trade

Trump Shocks Pharma With 100% Tariff On Imported Drugs Unless Companies Build In America ↗

September 25, 2025

Via Stocktwits

Topics Government

Does This Acquisition Make Pfizer Stock a Great Buy? ↗

September 25, 2025

There's an opportunity to get in on the weight-loss drug craze at a reasonable price.

Via The Motley Fool

Topics Death Intellectual Property

1 Reason Novo Nordisk (NVO) Is 1 of the Best Healthcare Stocks You Can Buy Today ↗

September 25, 2025

The latest data from the company's oral weight loss drug is bullish for the stock.

Via The Motley Fool

Topics Economy

3 Reasons to Buy Novo Nordisk Stock Right Now ↗

September 25, 2025

The pharmaceutical leader is gradually laying the groundwork for a strong rebound.

Via The Motley Fool

Direxion's Ultra-Leveraged CURE ETF Offers An Opportunity To Play The Potential Valuation Reset ↗

September 24, 2025

Via Benzinga

Topics ETFs

Scholar Rock, A Top 10% Stock, Dives After Catalent Issues Hamper SMA Drug ↗

September 23, 2025

Shares tumbled Tuesday after the FDA rejected the company's spinal muscular atrophy drug.

Via Investor's Business Daily

Top 5 Stocks to Watch in Q4 2025: Navigating a Shifting Economic Landscape

September 22, 2025

As the global economy marches towards the final quarter of 2025, investors find themselves at a pivotal juncture, balancing cautious optimism with an awareness of lingering uncertainties. Moderating...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

Big Pharma's Epicenter Shift: Eli Lilly and the Reshaping of the Weight-Loss Drug Market

September 22, 2025

The pharmaceutical industry is currently witnessing a transformative battle for dominance in the burgeoning weight-loss drug market, with Eli Lilly (NYSE: LLY) firmly at the forefront. What was once a...

Via MarketMinute

Topics Economy Intellectual Property

Roche Targets Top Spot In Weight Loss Drug Market ↗

September 22, 2025

Roche advances weight loss drug CT-388 to Phase III, boosts pipeline with major acquisitions.

Via Benzinga

Growth Titans: Eli Lilly's Weight-Loss Surge vs. Johnson & Johnson's Diversified Might

September 22, 2025

The pharmaceutical landscape is currently a tale of two giants employing vastly different, yet highly successful, growth strategies. Eli Lilly and Company (NYSE: LLY) has placed an extraordinary bet on...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

Eli Lilly's Ascent: A New Era in Obesity Treatment Driven by Zepbound and Orforglipron

September 22, 2025

Eli Lilly and Company (NYSE: LLY) has reported a stellar second quarter for 2025, significantly exceeding market expectations and cementing its position as a dominant force in the burgeoning obesity...

Via MarketMinute

Topics Economy

3 Dirt-Cheap Stocks to Buy Right Now ↗

September 22, 2025

These stocks share several common denominators, including attractive valuations.

Via The Motley Fool

Topics Intellectual Property

Pfizer Reportedly Nears Metsera Acquisition Deal: PFE Stock Climbs In Monday Pre-Market ↗

September 22, 2025

Pfizer Inc. (NYSE: PFE) stock climbed 1.87% in Monday pre-market amid reports that the company on the verge of acquiring Metsera Inc. (NASDAQ: MTSR), a developer of anti-obesity drugs.

Via Benzinga

NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) Emerges as a Top Affordable Growth Stock ↗

September 20, 2025

Novo Nordisk (NVO) is a top GARP stock with strong growth, exceptional profitability, and a reasonable valuation, making it a compelling investment opportunity.

Via Chartmill

Benzinga Bulls And Bears: Intel, FedEx, Cracker Barrel — And Markets Close At Record Highs ↗

September 20, 2025

Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.

Via Benzinga

Is Novo Nordisk Stock a Buy Now? ↗

September 20, 2025

A lot has gone wrong for the drugmaker recently.

Via The Motley Fool

Topics Economy

The Pharmaceutical Revolution: AI, Gene Therapies, and Obesity Drugs Reshape a Trillion-Dollar Market

September 19, 2025

The global pharmaceutical sector stands at the precipice of a monumental transformation, driven by an unprecedented convergence of scientific breakthroughs, technological innovation, and evolving...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

Could This New Drug Be The Safer Way To Fight Obesity? ↗

September 19, 2025

Skye Bioscience reported favorable Phase 1b nimacimab results, with analysts citing strong potential in obesity alongside GLP-1 therapies.

Via Benzinga

Eli Lilly's Dual Triumph: Mounjaro Expands Reach, Orforglipron Set to Revolutionize Oral Diabetes and Weight Loss Market

September 19, 2025

Eli Lilly (NYSE: LLY) is poised to further solidify its dominance in the burgeoning diabetes and weight loss markets following a cascade of overwhelmingly positive clinical trial results for its...

Via MarketMinute

Lilly's $5 Billion Virginia Investment: A Game Changer for GLP-1 and Oncology Drug Production

September 19, 2025

Eli Lilly and Company (NYSE: LLY) has announced a colossal $5 billion investment to establish a new, state-of-the-art manufacturing facility in Goochland County, Virginia. This significant expansion, a...

Via MarketMinute

Topics Artificial Intelligence Economy Government

Eli Lilly Poised for Blockbuster Q3 2025 with Skyrocketing EPS and Revenue Projections

September 19, 2025

Pharmaceutical giant Eli Lilly and Company (NYSE:LLY) is gearing up for a stellar third quarter of 2025, with analysts projecting massive earnings per share (EPS) and revenue growth. The optimistic...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

GLP-1 Titans Clash: Eli Lilly Challenges Novo Nordisk's Dominance in a Spiraling Market Battle

September 19, 2025

The pharmaceutical industry is witnessing an unprecedented showdown as Eli Lilly (NYSE: LLY) rapidly encroaches upon Novo Nordisk's (NYSE: NVO) long-held lead in the burgeoning GLP-1 (glucagon-like...

Via MarketMinute

Oscar Health Set For HIMS-Style Moonshot? Shorts Could Burn As ACA Buzz Builds ↗

September 19, 2025

Oscar Health (OSCR) is drawing comparisons to Hims & Hers (HIMS) as short sellers may trigger a moonshot with ACA subsidies and a potential government shutdown.

Via Benzinga

< Previous 1 2

...

13 14 15 16 17 18 19 20 21

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.